Abstract 1645P
Background
GN is front-line therapy for aPDAC. Addition of Cisplatin showed high overall response rate, progression free survival (PFS), and median overall survival (mOS) in aPDAC patients in a phase II study. However, biomarkers predicting response or resistance to GCN are lacking. We hypothesize that addition of cisplatin alters the aPDAC tumor microenvironment.
Methods
Analysis of 1379 aPDAC patients using Next-Gen sequencing (NGS) of the DNA (NextSeq, 592 genes or NovaSeq, WES) and RNA (NovaSeq, WTS) (Caris Life Sciences, Phoenix, AZ) was done to determine biomarkers of response to GCN versus GN (DNA damage repair mutations/DDRMs and stromal gene markers). Real-world mOS was extracted from insurance claims data and calculated using Kaplan-Meier estimates for molecularly defined cohorts from first treatment of GN or GCN to last contact. Time on treatment (ToT) was obtained similarly as the time of first treatment of GN or GCN to last treatment.
Results
1204 aPDAC patients received GN therapy among which 47% were female. 175 aPDAC patients received GCN regimen (47.5% were female). GCN was associated with higher mOS (534 vs 275 days(d), HR:0.61, p<0.001) and longer ToT (238 vs 105 d, HR:0.43, p<0.001) compared to GN. No difference in mOS and ToT was seen with either regimen in patients harboring somatic DDRMs (BRCA, CHEK, FANC, MSH, MLH and others). High STAT3 (957 vs 421 d, HR:0.44, p=0.017), ACTA2 (957 vs 421 d, HR:0.45, p=0.019) and SPARC (1029 vs 421 d, HR:0.49, p=0.038) gene expressions were associated with improvement in mOS on GCN whereas STAT2 had no association. Several stromal genes including TGFB1, TGFB2, HAS-2 and IL-6 correlated with worse mOS following GN therapy. High MMP-2 expression was associated with better mOS (p=0.007) and longer ToT (p=0.006) in patients who received GN.
Conclusions
GCN demonstrated higher mOS and ToT compared to GN. There was no difference in outcome among patients with somatic DDRMs. High expression of STAT3, ACTA2, and SPARC was associated with significant mOS benefit in patients who received GCN. In patients who received GN, MMP-2 was associated with better outcome. Analysis of stromal markers STAT3, ACTA2, and SPARC in a prospective trial is ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
T. Bekaii-Saab: Financial Interests, Institutional, Advisory Board: Bayer, Pfizer, Incyte, Ipsen, Seattle Genetics, Genentech, Merck KGA, Merus, Eisai, Servier; Financial Interests, Institutional, Other, DSMB: Merck; Financial Interests, Personal, Advisory Board: AbbVie, Boehringer Ingelheim, Janssen, AstraZeneca, Daiichi Sankyo, Natera, Celularity, Exact Science, Sobi, BeiGene, Xilis, Foundation Medicine, Stemline, Blueprint, Celularity, Caladrius, GSK, Deciphera, Zai Labs, Illumina, Sanofi; Financial Interests, Personal, Other, DSMB: AstraZeneca, Exelixis, The Valley Hospital, FibroGen; Financial Interests, Personal, Other, DSMC: PanCAN; Financial Interests, Personal, Royalties, WO/2018/183488: Human PD1 Peptide vaccines and uses thereof – Licensed to Imugene: Imugene; Financial Interests, Personal, Royalties, WO/2019/055687: Methods and compositions for the treatment of cancer Cachexia – Licensed to Recursion: Recursion; Financial Interests, Institutional, Research Grant: Agios, Arys, Bayer, Amgen, Ipsen, Clovis, Pfizer, Celgene, Novartis, Arcus, Atreca, BMS, Mirati, Merus, Abgenomics; Financial Interests, Institutional, Coordinating PI: Boston Biomedical, Incyte; Financial Interests, Institutional, Steering Committee Member: Seattle Genetics; Non-Financial Interests, Advisory Role: Imugene, Sun Biopharma. All other authors have declared no conflicts of interest.
Resources from the same session
1677P - Pancreatic enzyme replacement therapy improves survival in patients receiving nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma
Presenter: Daniele Lavacchi
Session: Poster session 22
1678P - A retrospective real-world study of nimotuzumab combined with chemotherapy for first-line treatment of advanced pancreatic cancer: A single center propensity score matched analysis
Presenter: Yinying Wu
Session: Poster session 22
1679P - Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: A systematic review and network meta-analysis
Presenter: Luca Mastrantoni
Session: Poster session 22
1680P - Meta-analysis of real-world survival outcomes of liposomal irinotecan in advanced pancreatic cancer patients with prior irinotecan exposure
Presenter: Amol Gupta
Session: Poster session 22
1681P - A retrospective real-world study for nimotuzumab plus postoperative adjuvant chemotherapy for resectable pancreatic cancer
Presenter: Siyi Zou
Session: Poster session 22
1682P - Impact of metastatic site on survival in patients with synchronous metastatic pancreatic adenocarcinoma (PDAC): A national prospective BACAP study
Presenter: Emily Alouani
Session: Poster session 22
1683TiP - Trial in progress: NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer-NEO-IMPACT
Presenter: Sarah Maloney
Session: Poster session 22
1684TiP - PARPiPANC: A multicentric, single arm, phase II assessing niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer
Presenter: Philippe Cassier
Session: Poster session 22
1685TiP - Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): A multicenter randomized controlled trial
Presenter: Jacob van Dam
Session: Poster session 22
1686TiP - Olaparib and durvalumab (MEDI4736) phase II study in patients with metastatic pancreatic cancer and DNA damage repair genes alterations
Presenter: Teresa Macarulla
Session: Poster session 22